Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation

Rachel Phelan; Annie Im; Rebecca L. Hunter; Yoshihiro Inamoto; Maria Teresa Lupo-Stanghellini; Alicia Rovo; Sherif M. Badawy; Linda Burns; Hesham Eissa; Hemant S. Murthy; Pinki Prasad; Akshay Sharma; Elizabeth Suelzer; Vaibhav Agrawal; Mahmoud Aljurf; Karen Baker; Grzegorz W. Basak; David Buchbinder; Zachariah DeFilipp; Lana Desnica Grkovic; Ajoy Dias; Hermann Einsele; Michael L. Eisenberg; Narendranath Epperla; Nosha Farhadfar; Arthur Flatau; Robert Peter Gale; Hildegard Greinix; Betty K. Hamilton; Shahrukh Hashmi; Peiman Hematti; Kareem Jamani; Dipnarine Maharaj; John Murray; Seema Naik; Sunita Nathan; Steven Pavletic; Zinaida Peric; Drazen Pulanic; Richard Ross; Andrea Salonia; Isabel Sanchez-Ortega; Bipin N. Savani; Tal Schechter; Ami J. Shah; Stephanie M. Smith; John A. Snowden; Amir Steinberg; Douglas Tremblay; Sarah C. Vij; Lauren Walker; Daniel Wolff; Jean A. Yared; Hélène Schoemans; André Tichelli

doi:10.1038/s41409-022-01591-z

Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation

Rachel Phelan^*, Annie Im, Rebecca L. Hunter, Yoshihiro Inamoto, Maria Teresa Lupo-Stanghellini, Alicia Rovo, Sherif M. Badawy, Linda Burns, Hesham Eissa, Hemant S. Murthy, Pinki Prasad, Akshay Sharma, Elizabeth Suelzer, Vaibhav Agrawal, Mahmoud Aljurf, Karen Baker, Grzegorz W. Basak, David Buchbinder, Zachariah DeFilipp, Lana Desnica GrkovicAjoy Dias, Hermann Einsele, Michael L. Eisenberg, Narendranath Epperla, Nosha Farhadfar, Arthur Flatau, Robert Peter Gale, Hildegard Greinix, Betty K. Hamilton, Shahrukh Hashmi, Peiman Hematti, Kareem Jamani, Dipnarine Maharaj, John Murray, Seema Naik, Sunita Nathan, Steven Pavletic, Zinaida Peric, Drazen Pulanic, Richard Ross, Andrea Salonia, Isabel Sanchez-Ortega, Bipin N. Savani, Tal Schechter, Ami J. Shah, Stephanie M. Smith, John A. Snowden, Amir Steinberg, Douglas Tremblay, Sarah C. Vij, Lauren Walker, Daniel Wolff, Jean A. Yared, Hélène Schoemans, André Tichelli

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Male-specific late effects after hematopoietic cell transplantation (HCT) include genital chronic graft-versus-host disease (GvHD), hypogonadism, sexual dysfunction, infertility, and subsequent malignancies. They may be closely intertwined and cause prolonged morbidity and decreased quality of life after HCT. We provide a systematic review of male-specific late effects in a collaboration between transplant physicians, endocrinologists, urologists, dermatologists, and sexual health professionals through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research, and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. The systematic review summarizes incidence, risk factors, screening, prevention and treatment of these complications and provides consensus evidence-based recommendations for clinical practice and future research.

Original language	English (US)
Pages (from-to)	1150-1163
Number of pages	14
Journal	Bone Marrow Transplantation
Volume	57
Issue number	7
DOIs	https://doi.org/10.1038/s41409-022-01591-z
State	Published - Jul 2022

ASJC Scopus subject areas

Transplantation
Hematology

Access to Document

10.1038/s41409-022-01591-z

Fingerprint

Dive into the research topics of 'Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation'. Together they form a unique fingerprint.

Cite this

Phelan, R., Im, A., Hunter, R. L., Inamoto, Y., Lupo-Stanghellini, M. T., Rovo, A., Badawy, S. M., Burns, L., Eissa, H., Murthy, H. S., Prasad, P., Sharma, A., Suelzer, E., Agrawal, V., Aljurf, M., Baker, K., Basak, G. W., Buchbinder, D., DeFilipp, Z., ... Tichelli, A. (2022). Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Bone Marrow Transplantation, 57(7), 1150-1163. https://doi.org/10.1038/s41409-022-01591-z

Phelan, Rachel ; Im, Annie ; Hunter, Rebecca L. et al. / Male-specific late effects in adult hematopoietic cell transplantation recipients : a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. In: Bone Marrow Transplantation. 2022 ; Vol. 57, No. 7. pp. 1150-1163.

@article{3ba3f3935bb74a6db89c27cfaa04165b,

title = "Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation",

abstract = "Male-specific late effects after hematopoietic cell transplantation (HCT) include genital chronic graft-versus-host disease (GvHD), hypogonadism, sexual dysfunction, infertility, and subsequent malignancies. They may be closely intertwined and cause prolonged morbidity and decreased quality of life after HCT. We provide a systematic review of male-specific late effects in a collaboration between transplant physicians, endocrinologists, urologists, dermatologists, and sexual health professionals through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research, and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. The systematic review summarizes incidence, risk factors, screening, prevention and treatment of these complications and provides consensus evidence-based recommendations for clinical practice and future research.",

author = "Rachel Phelan and Annie Im and Hunter, {Rebecca L.} and Yoshihiro Inamoto and Lupo-Stanghellini, {Maria Teresa} and Alicia Rovo and Badawy, {Sherif M.} and Linda Burns and Hesham Eissa and Murthy, {Hemant S.} and Pinki Prasad and Akshay Sharma and Elizabeth Suelzer and Vaibhav Agrawal and Mahmoud Aljurf and Karen Baker and Basak, {Grzegorz W.} and David Buchbinder and Zachariah DeFilipp and Grkovic, {Lana Desnica} and Ajoy Dias and Hermann Einsele and Eisenberg, {Michael L.} and Narendranath Epperla and Nosha Farhadfar and Arthur Flatau and Gale, {Robert Peter} and Hildegard Greinix and Hamilton, {Betty K.} and Shahrukh Hashmi and Peiman Hematti and Kareem Jamani and Dipnarine Maharaj and John Murray and Seema Naik and Sunita Nathan and Steven Pavletic and Zinaida Peric and Drazen Pulanic and Richard Ross and Andrea Salonia and Isabel Sanchez-Ortega and Savani, {Bipin N.} and Tal Schechter and Shah, {Ami J.} and Smith, {Stephanie M.} and Snowden, {John A.} and Amir Steinberg and Douglas Tremblay and Vij, {Sarah C.} and Lauren Walker and Daniel Wolff and Yared, {Jean A.} and H{\'e}l{\`e}ne Schoemans and Andr{\'e} Tichelli",

note = "Funding Information: The CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); HHSH250201700006C from the Health Resources and Services Administration (HRSA); and N00014-20-1-2705 and N00014-20-1-2832 from the Office of Naval Research; Support is also provided by Be the Match Foundation, the Medical College of Wisconsin, the National Marrow Donor Program, and from the following commercial entities: AbbVie; Accenture; Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies Corporation; Adienne SA; Allovir, Inc.; Amgen, Inc.; Astellas Pharma US; bluebird bio, inc.; Bristol Myers Squibb Co.; CareDx; CSL Behring; CytoSen Therapeutics, Inc.; Daiichi SankyoCo., Ltd; Eurofins Viracor; ExcellThera; Fate Therapeutics; Gamida-Cell, Ltd; Genentech Inc; Gilead; GlaxoSmithKline; Incyte Corporation; Janssen/Johnson & Johnson; Jasper Therapeutics; Jazz Pharmaceuticals, Inc.; Karyopharm Therapeutics; Kiadis Pharma; Kite, a Gilead Company; Kyowa Kirin; Magenta Therapeutics; Medac GmbH; Merck & Co.; Millennium, the Takeda Oncology Co.; Miltenyi Biotec, Inc.; MorphoSys; Novartis Pharmaceuticals Corporation; Omeros Corporation; Oncopeptides, Inc.; Orca Biosystems, Inc.; Pfizer, Inc.; Pharmacyclics, LLC; Sanofi Genzyme; Seagen, Inc.; Stemcyte; Takeda Pharmaceuticals; Tscan; Vertex; Vor Biopharma; Xenikos BV. Funding Information: HE reports grants and other from BMS/Celgene, grants and other from Janssen, grants and other from Amgen, other from Takeda, grants and other from Sanofi, grants and other from GSK, during the conduct of the study. SH reports other from Pfizer, other from Novartis, other from Therakos, other from Janssen, other from MSD, outside the submitted work. YI reports personal fees from Novartis, personal fees from Janssen, personal fees from Meiji Seika Pharma, outside the submitted work. RP reports research funding from Amgen. RR reports other from Diurnal Plc, during the conduct of the study. HS reports participation in advisory boards for Janssen & Novartis; speaker{\textquoteright}s fees from Incyte, Jazz Pharmaceuticals, Takeda, Novartis and the BHS (Belgian Hematological Society); travel grants from EBMT, CIBMTR, Incyte & Gilead and research funding from Novartis & the BHS, outside of the submitted work. AR reports grants from Novartis, grants from CSL Behring, grants from Alexion, personal fees from Novartis, personal fees from BMS, personal fees from OrPha Swiss GmbH, other from Amgen, other from AstraZeneca, other from Sanofi, other from Celgene, outside the submitted work. ASharma reports clinical trial salary support from Vertex Pharmaceuticals, CRISPR Therapeutics, Novartis paid to his institution, and personal consultancy fees from Spotlight Therapeutics, outside the submitted work. JAS reports personal fees from MEDAC, personal fees from KIADIS, personal fees from GILEAD, personal fees from JANSSEN, personal fees from MALLINCKRODT, personal fees from JAZZ, personal fees from ACTELION, outside the submitted work. DW reports grants and personal fees from Novartis, personal fees from Mallinckrodt, personal fees from Behring, outside the submitted work. PG is a consultant to Ascenage Pharma, BeiGene Ltd, Kite Pharma Inc., Fusion Pharma LLC, LaJolla NanoMedical Inc., Mingsight Parmaceuticals Inc. and CStone Pharmaceuticals; Medical Director, FFF Enterprises Inc.; Partner, AZCA Inc.; Board of Directors, RakFond Foundation for Cancer Research Support; Scientific Advisory Board, Antegene Biotech LLC and StemRad Ltd. Funding Information: The CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); HHSH250201700006C from the Health Resources and Services Administration (HRSA); and N00014-20-1-2705 and N00014-20-1-2832 from the Office of Naval Research; Support is also provided by Be the Match Foundation, the Medical College of Wisconsin, the National Marrow Donor Program, and from the following commercial entities: AbbVie; Accenture; Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies Corporation; Adienne SA; Allovir, Inc.; Amgen, Inc.; Astellas Pharma US; bluebird bio, inc.; Bristol Myers Squibb Co.; CareDx; CSL Behring; CytoSen Therapeutics, Inc.; Daiichi SankyoCo., Ltd; Eurofins Viracor; ExcellThera; Fate Therapeutics; Gamida-Cell, Ltd; Genentech Inc; Gilead; GlaxoSmithKline; Incyte Corporation; Janssen/Johnson & Johnson; Jasper Therapeutics; Jazz Pharmaceuticals, Inc.; Karyopharm Therapeutics; Kiadis Pharma; Kite, a Gilead Company; Kyowa Kirin; Magenta Therapeutics; Medac GmbH; Merck & Co.; Millennium, the Takeda Oncology Co.; Miltenyi Biotec, Inc.; MorphoSys; Novartis Pharmaceuticals Corporation; Omeros Corporation; Oncopeptides, Inc.; Orca Biosystems, Inc.; Pfizer, Inc.; Pharmacyclics, LLC; Sanofi Genzyme; Seagen, Inc.; Stemcyte; Takeda Pharmaceuticals; Tscan; Vertex; Vor Biopharma; Xenikos BV. Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = jul,

doi = "10.1038/s41409-022-01591-z",

language = "English (US)",

volume = "57",

pages = "1150--1163",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "7",

}

Phelan, R, Im, A, Hunter, RL, Inamoto, Y, Lupo-Stanghellini, MT, Rovo, A, Badawy, SM, Burns, L, Eissa, H, Murthy, HS, Prasad, P, Sharma, A, Suelzer, E, Agrawal, V, Aljurf, M, Baker, K, Basak, GW, Buchbinder, D, DeFilipp, Z, Grkovic, LD, Dias, A, Einsele, H, Eisenberg, ML, Epperla, N, Farhadfar, N, Flatau, A, Gale, RP, Greinix, H, Hamilton, BK, Hashmi, S, Hematti, P, Jamani, K, Maharaj, D, Murray, J, Naik, S, Nathan, S, Pavletic, S, Peric, Z, Pulanic, D, Ross, R, Salonia, A, Sanchez-Ortega, I, Savani, BN, Schechter, T, Shah, AJ, Smith, SM, Snowden, JA, Steinberg, A, Tremblay, D, Vij, SC, Walker, L, Wolff, D, Yared, JA, Schoemans, H & Tichelli, A 2022, 'Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation', Bone Marrow Transplantation, vol. 57, no. 7, pp. 1150-1163. https://doi.org/10.1038/s41409-022-01591-z

Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. / Phelan, Rachel; Im, Annie; Hunter, Rebecca L. et al.
In: Bone Marrow Transplantation, Vol. 57, No. 7, 07.2022, p. 1150-1163.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Male-specific late effects in adult hematopoietic cell transplantation recipients

T2 - a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation

AU - Phelan, Rachel

AU - Im, Annie

AU - Hunter, Rebecca L.

AU - Inamoto, Yoshihiro

AU - Lupo-Stanghellini, Maria Teresa

AU - Rovo, Alicia

AU - Badawy, Sherif M.

AU - Burns, Linda

AU - Eissa, Hesham

AU - Murthy, Hemant S.

AU - Prasad, Pinki

AU - Sharma, Akshay

AU - Suelzer, Elizabeth

AU - Agrawal, Vaibhav

AU - Aljurf, Mahmoud

AU - Baker, Karen

AU - Basak, Grzegorz W.

AU - Buchbinder, David

AU - DeFilipp, Zachariah

AU - Grkovic, Lana Desnica

AU - Dias, Ajoy

AU - Einsele, Hermann

AU - Eisenberg, Michael L.

AU - Epperla, Narendranath

AU - Farhadfar, Nosha

AU - Flatau, Arthur

AU - Gale, Robert Peter

AU - Greinix, Hildegard

AU - Hamilton, Betty K.

AU - Hashmi, Shahrukh

AU - Hematti, Peiman

AU - Jamani, Kareem

AU - Maharaj, Dipnarine

AU - Murray, John

AU - Naik, Seema

AU - Nathan, Sunita

AU - Pavletic, Steven

AU - Peric, Zinaida

AU - Pulanic, Drazen

AU - Ross, Richard

AU - Salonia, Andrea

AU - Sanchez-Ortega, Isabel

AU - Savani, Bipin N.

AU - Schechter, Tal

AU - Shah, Ami J.

AU - Smith, Stephanie M.

AU - Snowden, John A.

AU - Steinberg, Amir

AU - Tremblay, Douglas

AU - Vij, Sarah C.

AU - Walker, Lauren

AU - Wolff, Daniel

AU - Yared, Jean A.

AU - Schoemans, Hélène

AU - Tichelli, André

N1 - Funding Information: The CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); HHSH250201700006C from the Health Resources and Services Administration (HRSA); and N00014-20-1-2705 and N00014-20-1-2832 from the Office of Naval Research; Support is also provided by Be the Match Foundation, the Medical College of Wisconsin, the National Marrow Donor Program, and from the following commercial entities: AbbVie; Accenture; Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies Corporation; Adienne SA; Allovir, Inc.; Amgen, Inc.; Astellas Pharma US; bluebird bio, inc.; Bristol Myers Squibb Co.; CareDx; CSL Behring; CytoSen Therapeutics, Inc.; Daiichi SankyoCo., Ltd; Eurofins Viracor; ExcellThera; Fate Therapeutics; Gamida-Cell, Ltd; Genentech Inc; Gilead; GlaxoSmithKline; Incyte Corporation; Janssen/Johnson & Johnson; Jasper Therapeutics; Jazz Pharmaceuticals, Inc.; Karyopharm Therapeutics; Kiadis Pharma; Kite, a Gilead Company; Kyowa Kirin; Magenta Therapeutics; Medac GmbH; Merck & Co.; Millennium, the Takeda Oncology Co.; Miltenyi Biotec, Inc.; MorphoSys; Novartis Pharmaceuticals Corporation; Omeros Corporation; Oncopeptides, Inc.; Orca Biosystems, Inc.; Pfizer, Inc.; Pharmacyclics, LLC; Sanofi Genzyme; Seagen, Inc.; Stemcyte; Takeda Pharmaceuticals; Tscan; Vertex; Vor Biopharma; Xenikos BV. Funding Information: HE reports grants and other from BMS/Celgene, grants and other from Janssen, grants and other from Amgen, other from Takeda, grants and other from Sanofi, grants and other from GSK, during the conduct of the study. SH reports other from Pfizer, other from Novartis, other from Therakos, other from Janssen, other from MSD, outside the submitted work. YI reports personal fees from Novartis, personal fees from Janssen, personal fees from Meiji Seika Pharma, outside the submitted work. RP reports research funding from Amgen. RR reports other from Diurnal Plc, during the conduct of the study. HS reports participation in advisory boards for Janssen & Novartis; speaker’s fees from Incyte, Jazz Pharmaceuticals, Takeda, Novartis and the BHS (Belgian Hematological Society); travel grants from EBMT, CIBMTR, Incyte & Gilead and research funding from Novartis & the BHS, outside of the submitted work. AR reports grants from Novartis, grants from CSL Behring, grants from Alexion, personal fees from Novartis, personal fees from BMS, personal fees from OrPha Swiss GmbH, other from Amgen, other from AstraZeneca, other from Sanofi, other from Celgene, outside the submitted work. ASharma reports clinical trial salary support from Vertex Pharmaceuticals, CRISPR Therapeutics, Novartis paid to his institution, and personal consultancy fees from Spotlight Therapeutics, outside the submitted work. JAS reports personal fees from MEDAC, personal fees from KIADIS, personal fees from GILEAD, personal fees from JANSSEN, personal fees from MALLINCKRODT, personal fees from JAZZ, personal fees from ACTELION, outside the submitted work. DW reports grants and personal fees from Novartis, personal fees from Mallinckrodt, personal fees from Behring, outside the submitted work. PG is a consultant to Ascenage Pharma, BeiGene Ltd, Kite Pharma Inc., Fusion Pharma LLC, LaJolla NanoMedical Inc., Mingsight Parmaceuticals Inc. and CStone Pharmaceuticals; Medical Director, FFF Enterprises Inc.; Partner, AZCA Inc.; Board of Directors, RakFond Foundation for Cancer Research Support; Scientific Advisory Board, Antegene Biotech LLC and StemRad Ltd. Funding Information: The CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); HHSH250201700006C from the Health Resources and Services Administration (HRSA); and N00014-20-1-2705 and N00014-20-1-2832 from the Office of Naval Research; Support is also provided by Be the Match Foundation, the Medical College of Wisconsin, the National Marrow Donor Program, and from the following commercial entities: AbbVie; Accenture; Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies Corporation; Adienne SA; Allovir, Inc.; Amgen, Inc.; Astellas Pharma US; bluebird bio, inc.; Bristol Myers Squibb Co.; CareDx; CSL Behring; CytoSen Therapeutics, Inc.; Daiichi SankyoCo., Ltd; Eurofins Viracor; ExcellThera; Fate Therapeutics; Gamida-Cell, Ltd; Genentech Inc; Gilead; GlaxoSmithKline; Incyte Corporation; Janssen/Johnson & Johnson; Jasper Therapeutics; Jazz Pharmaceuticals, Inc.; Karyopharm Therapeutics; Kiadis Pharma; Kite, a Gilead Company; Kyowa Kirin; Magenta Therapeutics; Medac GmbH; Merck & Co.; Millennium, the Takeda Oncology Co.; Miltenyi Biotec, Inc.; MorphoSys; Novartis Pharmaceuticals Corporation; Omeros Corporation; Oncopeptides, Inc.; Orca Biosystems, Inc.; Pfizer, Inc.; Pharmacyclics, LLC; Sanofi Genzyme; Seagen, Inc.; Stemcyte; Takeda Pharmaceuticals; Tscan; Vertex; Vor Biopharma; Xenikos BV. Publisher Copyright: © 2022, The Author(s).

PY - 2022/7

Y1 - 2022/7

N2 - Male-specific late effects after hematopoietic cell transplantation (HCT) include genital chronic graft-versus-host disease (GvHD), hypogonadism, sexual dysfunction, infertility, and subsequent malignancies. They may be closely intertwined and cause prolonged morbidity and decreased quality of life after HCT. We provide a systematic review of male-specific late effects in a collaboration between transplant physicians, endocrinologists, urologists, dermatologists, and sexual health professionals through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research, and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. The systematic review summarizes incidence, risk factors, screening, prevention and treatment of these complications and provides consensus evidence-based recommendations for clinical practice and future research.

AB - Male-specific late effects after hematopoietic cell transplantation (HCT) include genital chronic graft-versus-host disease (GvHD), hypogonadism, sexual dysfunction, infertility, and subsequent malignancies. They may be closely intertwined and cause prolonged morbidity and decreased quality of life after HCT. We provide a systematic review of male-specific late effects in a collaboration between transplant physicians, endocrinologists, urologists, dermatologists, and sexual health professionals through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research, and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. The systematic review summarizes incidence, risk factors, screening, prevention and treatment of these complications and provides consensus evidence-based recommendations for clinical practice and future research.

UR - http://www.scopus.com/inward/record.url?scp=85129492511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85129492511&partnerID=8YFLogxK

U2 - 10.1038/s41409-022-01591-z

DO - 10.1038/s41409-022-01591-z

M3 - Article

C2 - 35523848

AN - SCOPUS:85129492511

SN - 0268-3369

VL - 57

SP - 1150

EP - 1163

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 7

ER -

Phelan R, Im A, Hunter RL, Inamoto Y, Lupo-Stanghellini MT, Rovo A et al. Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Bone Marrow Transplantation. 2022 Jul;57(7):1150-1163. doi: 10.1038/s41409-022-01591-z

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this